Xeris Biopharma Posts Encouraging Data From Reformulated Thyroid Hormone Deficiency Treatment In Healthy Participants
Xeris Biopharma Holdings Inc (NASDAQ:XERS) announced topline results from its Phase 1 study of subcutaneous (SC) levothyroxine (XP-8121) in healthy adult…